Researchers found that pairing the antibiotic rifampicin with a second compound turned multidrug resistance into a weakness—providing proof of concept for using basic science to design life-saving ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...